Digital Biotechnologies Inc. has secured funding as part of an initial closing of a Series A investment round that could reach $15 million. This Seattle-based subsidiary of Adaptive Biotechnologies, which specializes in immune medicine, operates from the headquarters of its parent company in the South Lake Union area.
The startup's focus is on creating advanced DNA sequencing technology, aiming to develop a "clinical sequencing instrument" that addresses current limitations in high-throughput sequencing applications. Notably, existing platforms often fall short in terms of accuracy, speed, and cost-effectiveness, which hampers their clinical utility.
Adaptive Biotechnologies will hold nearly half of Digital Biotechnologies upon the completion of this funding round. A spokesperson expressed confidence in the startup's progress and potential, emphasizing the collaboration with academic and industry experts. Jason Bielas, a professor at the University of Washington, is among the co-founders of Digital Biotechnologies, which has a small team listed on LinkedIn.